Car- vedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circula- tion. 1996;94:2807 16. 44. Boehringer Ingelheim Pharmaceuticals. Empagli- ozin meets primary endpoint in Phase III heart failure trial [Press Release] Published July 30, 2020. Available at: https://www.boehringer-ingelheim.in/press- release/empagli ozin-meets-primary-endpoint-phase- iii-heart-failure-trial. Accessed October 15, 2020. 45. Solomon SD, Jhund PS, Claggett BL, et al. Effect of dapagli ozin in patients with HFrEF treated with sacubitril/valsartan: the DAPA-HF Trial. J Am Coll Cardiol HF. 2020;8:811 8. 46. Honigberg MC, Vardeny O, Vaduganathan M. Practical considerations for the use of sodium-glucose co-transporter inhibitors in heart failure. Circ Heart Fail. 2020;13:e006623. 47. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049 57. 48. Testani JM, Stevens SR, Brisco MA, et al. In- uence of diuretic dose and route of administration on loop diuretic ef ciency: insights from the Diuretic Optimization Strategies Evaluation in Acute Heart Failure (DOSE-AHF) trial. J Card Fail. 2014; 20:S40. 49. Fera LE, MacLean TE, Fischer CM, et al. Navigator- driven remote optimization of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction: program design and initial feasibility. J Card Fail. 2018;24:S99. 50. Gorodeski EZ, Goyal P, Cox ZL, et al. Virtual visits for care of patients with heart failure in the era of COVID-19: a statement from the Heart Failure Society of America. J Card Fail. 2020;26:448 56. 51. Forman DE, Sanderson BK, Josephson RA, et al. Heart failure as a newly approved diagnosis for cardiac rehabilitation: challenges and opportunities. J Am Coll Cardiol. 2015;65:2652 9. 52. DeFilippis EM, Reza N, Donald E, et al. Consider- ations for heart failure during the COVID-19 pandemic. J Am Coll Cardiol HF. 2020;8:681 91. 53. 